Serotonergic Function in Obsessive-Compulsive Disorder: Behavioral and Neuroendocrine Responses to Oral m-Chlorophenylpiperazine and Fenfluramine in Patients and Healthy Volunteers

Archives of General Psychiatry

Volumn 49, Issue 1, 1992, Pages 21-28

  Hollander, Eric ^a   Decaria, Concetta M ^a   Nitescu, Anca ^a   Gully, Robert ^a   Suckow, Raymond F ^a   Cooper, Thomas B ^a   Gorman, Jack M ^a   Klein, Donald F ^a   Liebowitz, Michael R ^a  

^a Department of Psychiatry College of Physicians and Surgeons Columbia University Obsessive Compulsive Disorder Biological Studies Program New York State Psychiatric Institute ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CLONIDINE; FENFLURAMINE; HYDROCORTISONE; NORFENFLURAMINE; PROLACTIN; SEROTONIN; SEROTONIN RECEPTOR;

ADULT; ARTICLE; BEHAVIOR; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOCRINE FUNCTION; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROENDOCRINE SYSTEM; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SEROTONINERGIC SYSTEM;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; FENFLURAMINE; HUMAN; HYDROCORTISONE; MALE; MIDDLE AGE; OBSESSIVE-COMPULSIVE DISORDER; PIPERAZINES; PLACEBOS; PROLACTIN; RECEPTORS, SEROTONIN; SEROTONIN; SUPPORT, U.S. GOV'T, P.H.S.; UP-REGULATION;

EID: 0026519130     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1992.01820010021003     Document Type: Article

References (97)

1. Myers JK, Weissman MM, Tischler GL, Holzer CE, Leaf PJ, Orvaschel H, Anthony JC, Boyd JH, Burke JD, Kramer M, Stoltzman R. Six-month prevalence of psychiatric disorders in three communities: 1980 to 1982. Arch Gen Psychiatry. 1984;41:959-967.
2. Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD, Regier DA. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry. 1984;41:949-958.
3. Ananth J, Pecknold JC, Van Den Steen N, Engelsmann F. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol Biol Psychiatry. 1981;5:257-262.
4. Flament MF, Rapoport JL, Berg CJ, Sceery W, Kilts C, Mellstrom B, Linnoila M. Clomipramine treatment of childhood obsessive-compulsive disorder, a double-blind controlled study. Arch Gen Psychiatry. 1985;42:977-983.
5. Mavissakalian M, Turner SM, Michelson L, Jacob R. Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II. Am J Psychiatry. 1985;142:572-576.
6. Insel TR, Murphy DL, Cohen RM, Alterman I, Lilts C, Linnoila M. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry. 1983;40:605-612.
7. Marks IM, Stern RS, Mawson D, Cobb J, McDonald R. Clomipramine and exposure for obsessive-compulsive rituals, I. Br J Psychiatry. 1980;136:1-25.
8. Montgomery SA. Clomipramine in obsessional neurosis: a placebo-controlled trial. Pharm Med. 1980;37:1281-1285.
9. Rapoport J, Elkins R, Mikkelson E. Clinical controlled trials of chlorimipramine in adolescents with obsessivecompulsive disorder. Psychopharmacol Bull. 1980;16:61-63.
10. Stern RS, Marks IM, Wright J, Luscombe DK. Clomipramine: plasma levels, side effects and outcome in obsessivecompulsive neurosis. Postgrad Med J. 1980;56:134-139.
11. Renynghe de Voxrie GV. Anafranil (G 34586) in obsessive neurosis. Acta Neurol Belg. 1968;68:787-792.
12. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder, I: a controlled clinical trial. Arch Gen Psychiatry. 1980;37:1281-1285.
13. Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Res. 1985;14:85-93.
14. Yaryura-Tobias JA, Neziroglu F, Bergman L. Chlorimipramine, for obsessive-compulsive neurosis: an organic approach. Curr Ther Res. 1976;20:541-548.
15. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry. 1987;22:667-687.
16. DeVaugh-Geiss J, Landau P, Katz R. Treatment of obsessive-compulsive disorder with clomipramine. Psychiatric Annals. 1989;19:97-101.
17. Liebowitz MR, Hollander E, Campeas R, Schneier F, Hatterer J, Papp L, Sandberg D, Davies S, Stein M. Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial. J Clin Psychopharmacol. 1989;9:423-427.
18. Turner SM, Jacob RG, Geidel DC, Himmelhoch J. Fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol. 1985;5:207-212.
19. Fontaine R, Chouinard G. Fluoxetine in the treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9:605-608.
20. Fontaine R, Chouinard G. Fluoxetine in the long term maintenance treatment of obsessive-compulsive disorder. Psychiatric Annals. 1989;19:88-91.
21. Price LH, Goodman WK, Charney DS, Rasmussen SA, Heninger GR. Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry. 1987;144:1059-1061.
22. Perse TL, Greist TH, Jefferson JW, Rosenfeld R, Dar R. Fluvoxamine treatment of obsessive-compulsive disorders. Am J Psychiatry. 1987;144:1543-1548.
23. Goodman W, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DA. Efficacy of fluvoxamine in obsessive-compulsive disorder. Arch Gen Psychiatry. 1989;46:1, 36-44.
24. Kahn RS, Westenberg HGM, Jolles J. Zimelidine treatment of obsessive-compulsive disorder. Acta Psychiatr Scand. 1984;69:259-261.
25. Prasad A. A double-blind study of imipramine versus' zimelidine in treatment of obsessive-compulsive neurosis. Pharmacopsychiatry. 1984;17:61-62.
26. Leonard HL. Drug treatment of obsessive-compulsive disorder. In: Rapoport JL, ed. Obsessive-Compulsive Disorder in Children and Adolescents. Washington, DC: American Psychiatric Press; 1989:217-236.
27. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry. 1985;20:1174-1188.
28. Flament MF, Rapoport JL, Murphy DL, Berg CJ, Lake R. Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry. 1987;44:219-225.
29. Thoren P, Asberg M, Bertilsson L, Mellstrom B, Sjöqvist F, Traskman L. Clomipramine treatment of obsessivecompulsive disorder, II: biochemical aspects. Arch Gen Psychiatry. 1980;37:1289-1294.
30. Goodman WK, Price L, Anderson GM, Palumbo JH, Charney DS, Heninger GR. Drug response and obsessivecompulsive subtypes. Presented at the American Psychiatric Association Annual Meeting (Symposium 5C); May 8,1989; San Francisco, Calif.
31. Fuller RW, Snoddy HD, Mason NR, Owen JE. Dispositions and pharmacological effect of M-CPP in rats. Neuropharmacology. 1981;20:155-162.
32. Invernizzi R, Cotecchia S, DeBlasi A, Mennini T, Pataccini R, Samanin R. Effects of m-chlorophenylpiperazine on receptor binding and brain metabolism of monoamines in rats. Neurochem Int. 1981;3:239-244.
33. Rokosz-Pelc A, Antkiewics-Michaluk L, Vetulai J. 5-Hydroxytryptamine-like properties of m-chlorophenylpiperazine: comparison with quipazine. J Pharm Pharmacol. 1980;32:220-222.
34. Samanin R, Mennini T, Perrer A. M-CPP: A central 5HT agonist causing powerful anorexia in rats. Naunyn Schmiedebergs Arch Pharmacol. 1979;308:159-163.
35. Mennini T, Poggasi E, Caccia S, Bendotti C, Borsini F, Samanin R. Adaptive changes in central serotonin receptors after long-term treatment in rats. In: Littauer UZ, Dudai Y, Silman I, eds. Neurotransmitters and Their Receptors. New York, NY: John Wiley & Sons Inc; 1980:101-108.
36. Vetulani J, Sansone M, Bednarczyk B, Hano J. Different effects of 3-chlorophenylpiperazine on locomotor activity and acquisition of conditioned avoidance response in different strains of mice. Naunyn Schmiedebergs Arch Pharmacol. 1982;319:217-274.
37. Maj J, Lewandowska A. Central serotoninmimetic action of phenylpiperazines. Pol J Pharmacol Pharm. 1980;32:495-504.
38. Aloi JA, Insel TR, Mueller EA, Murphy DL. Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys. Life Sci. 1984;34:1325-1331.
39. Quattrone A, Schettini G, Anunziato L, DeRenzo G. Pharmacological evidence of super-sensitivity of central serotonergic receptors involved in control of prolactin secretion. Eur J Pharmacol. 1981;76:9-13.
40. Cohen ML, Fuller RW. Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine and m-trifluoromethylpiperazine. Life Sci. 1983;32:711-718.
41. Mueller EA, Murphy DL, Sunderland T. Neuroendocrine effects of M-CPP, a 5HT agonist, in humans. J Clin Endocrinol Metab. 1985;61:1179-1184.
42. Mueller EA, Murphy DL, Sunderland T. Further studies of the putative serotonin agonsit, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology. 1986;89:388-391.
43. Hamik A, Peroutka SJ. 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry. 1989;25:569-575.
44. Hoyer D. Functional correlates of serotonin 5-HT-1 recognition sites. J Receptor Res. 1988;8:59-81.
45. Smith TM, Suckow RF. Trazodone and m-chlorophenylpiperazine: concentration in brain and receptor activity in regions in the brain associated with anxiety. Neuropharmacology. 1985;24:1067-1071.
46. Bagdy G, Calogero AE, Murphy DL, Szemeredi K. Serotonin agonists cause parallel activation of the sympathoadrenomedullary system and the hypothalamo-pituitaryadrenocortical axis in conscious rats. Endocrinology. 1989;125:2664-2669.
47. Sanders-Bush E, Conn PJ. Neurochemistry of serotonin neuronal systems: consequences of serotonin receptor activation. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:95-103.
48. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL. Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry. 1987;44:946-951.
49. Hollander E, Fay M, Cohen B, Campeas R, Gorman JM, Liebowitz MR. Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. Am J Psychiatry. 1988;145:1015-1017.
50. Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR. Serotonin function in obsessivecompulsive disorder. Arch Gen Psychiatry. 1988;45:177-185.
51. Pigott TA, Murphy DL, Pato MT, Hill JL, Grover G, Benkelfat C. Serotonin probes in obsessive-compulsive disorder. Presented at the Annual Meeting of the American Psychiatric Association; May 8, 1989; San Francisco, Calif.
52. Gorman JM, Liebowitz MR, Fyer AJ, Dillon D, Davies SO, Stein J, Klein DF. Lactate infusions in obsessive-compulsive disorder. Am J Psychiatry. 1985;142:864-866.
53. Rasmussen SA, Goodman WK, Woods SW, Heninger GK, Charney DS. Effects of yohimbine in obsessive-compulsive disorder. Psychopharmacology. 1987;93:308-313.
54. Zohar J, Klein EM, Mueller EA, Insel TR, Uhde TW, Murphy DL. 5HT, obsessive-compulsive disorders and anxiety. Presented at the Annual Meeting of the American Psychiatric Association, May 14, 1987; Chicago, III.
55. Bastani B, Nash JF, Meltzer HY. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessivecompulsive disorder. Arch Gen Psychiatry. 1990;47:833-839.
56. Costa EA, Gropetti A, Revuelta A. Action of fenfluramine on monoamine stores of rat tissue. Br J Pharmacol. 1971;41:57-64.
57. Borroni E, Ceci A, Garratini S, Mennini T. Differences between D-fenfluramine and D-norfenfluramine in serotonin presynaptic mechanisms. I Neurochem. 1983;40:891-893.
58. Fuxe K, Farnebo LO, Hamberger B, Ogren SO. On the in vivo and in vitro actions of fenfluramine and its derivatives on central monoamine neurons especially, 5-hydroxytryptamine neurons, and their relation to the anorectic activity of fenfluramine. Postgrad MedJ. 1975;51(suppl 1):35-45.
59. Invernizzi R, Kmieciak-Kolada K, Samanin R. Is receptor activation involved in the mechanism by which (+)fenfluramine (+)norfenfluramine deplete 5-hydroxytryptophan in the rat brain? Br J Pharmacol. 1982;75:525-530.
60. Quattrone A, Schettini G, DiRenzo G, Amoroso S, Annunziato L. An in vivo useful tool to evaluate the activity of serotonin uptake inhibitors: prevention by chlorimipramine of the prolactin releasing action of d-fenfluramine. Adv Biochem Psychopharmacol. 1982;31:229-234.
61. Rowland NE, Carlton J. Neurobiology of an anorectic drug: fenfluramine. Prog Neurobiol. 1986;27:13-62.
62. Siever LJ, Murphy DL, Slater S, de la Vega E, Lipper S. Plasma prolactin changes following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsivity in depression. Life Sci. 1984;34:1029-1039.
63. Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Cooper TB, Mohs RC, Davis KL. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry. 1989;46:587-599.
64. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann R, Hill C, Heninger GR, Charney DS. The YaleBrown Obsessive Compulsive Scale (Y-BOCS), I: development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006-1011.
65. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. Yale-Brown Obsessive Compulsive Scale (Y-BOCS), II: validity. Arch Gen Psychiatry. 1989;46:1012-1016.
66. Goodman WK, Price LH. Rating scales for obsessivecompulsive disorders. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders: Theory and Management. 2nd ed. St Louis, Mo: Mosby—Year Book; 1990:154-166.
67. Kahn RS, Wetzler S, Asnis GM, Kling MA, Suckow RF, van Praag HM. Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study. Psychopharmacology. 1990;100:339-344.
68. Suckow RF, Cooper TB, Kahn R. High performance liquid chromatography method for analysis of plasma metachloropiperazine. J Chromatogr. 1990;528:228-234.
69. Hollander E, Schiffman E, Cohen B, Rivera-Stein M, Rosen W, Gorman JM, Fyer A, Papp L, Liebowitz MR. Signs of central nervous system dysfunction in obsessive-compulsive disorder. Arch Gen Psychiatry. 1990;47:27-32.
70. Hollander E, DeCaria C, Liebowitz MR. Predictors of treatment outcome in obsessive-compulsive disorder. Presented at the Annual Meeting of the American Psychiatric Association; May 8, 1989; San Francisco, Calif.
71. Hollander E, DeCaria CM, Saoud JB, Klein DF, Liebowitz MR. Neurological soft signs in obsessive-compulsive disorder (response to Bihari et al). Arch Gen Psychiatry. 1991;48:278-279.
72. Zohar J, Insel TR, Zohar-Kadouch RL, Hill JL, Murphy DL. Serotonergic responsivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Arch Gen Psychiatry. 1988;45:167-172.
73. Hollander E, DeCaria C, Gulley R, Nitescu A, Suckow RF, Gorman JG, Klein DF, Liebowitz MR. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine response to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res. In press.
74. Fuxe K, Ogren SO, Agnati LF, Benfenati F, Fredholm B, Anderson K, Zini I, Eneroth R. Chronic antidepressant treatment and central 5-HT synapses. Neuropharmacology. 1983;22:389-400.
75. Ogren SO, Fuxe K, Agnati L. The importance of brain serotonergic mechanisms for the action of antidepressant drugs. Pharmacopsychiatry. 1985;18:209-213.
76. Frazer A, Brunswick DJ. Antidepressant drugs. In: DiPalma JR, DiGregor GJ, eds. Basic Pharmacology and Medicine. 3rd ed. New York, NY: McGraw-Hill International Book Co; 1989:266-279.
77. Benkelfat C, Murphy DL, Zohar J, Hill JL, Grover G, Insel TR. Clomipramine in obsessive-compulsive disorder: further evidence for a serotonergic mechanism of action. Arch Gen Psychiatry. 1989;46:23-28.
78. Murphy DL, Zohar J, Benkelfat C, Pato MT, Pigott TA, Insel TR. Obsessive-compulsive disorder as a 5-HT subsystemrelated behavioral disorder. Br J Psychiatry. 1989;155(suppl 8):15-24.
79. Mueller GP, Twohy CP, Chen HT, Advis JP, Meites J. Effect of L-tryptophan and restraint stress on hypothalamic and brain serotonin turnover, and pituitary TSH and prolactin release in rats. Life Sci. 1976;18:715-724.
80. Caccia S, Fong MH, Garattini S, Zanini MG. Plasma concentrations of trazodone and 1-(3-chlorophenyl)piperazine in man after a single oral dose of trazodone. J Pharm Pharmacol. 1982;34:605-606.
81. Caccia S, Ballabio M, Samanin R. (-)-m-Chlorophenylpiperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone. J Pharm Pharmacol. 1981;33:477-478.
82. Sills MA, Wolfe BB, Frazer A. Determination of selective and nonselective compounds for the 5-HT1A and 5-HT1B receptor subtypes in rat frontal cortex. J Pharmacol Exp Ther. 1984;231:480-487.
83. Peroutka SJ. Selective labeling of 5-HT1A and 5-HT1B binding sites in bovine brain. Brain Res. 1985;344:167-171.
84. Heninger GR, Krystal JH, Smith A. Effects of D,- and D2-receptor antagonists and 5-HT receptor agonists and antagonists on neuroendocrine function in rhesus monkeys. Avstr SocNeurosci. 1988;324:7. Abstract.
85. Pilottle NS, Porter JC. Dopamine in hypophyseal portal plasma and prolactin in systemic plasma of rats treated with 5-hydroxytryptamine. Endocrinology. 1981;108:2137-2141.
86. Kaji H, Chihara K, Minamitani N, Kodama H, Kita T, Fujita T. Effects of various catecholamine antagonists on prolactin secretion in conscious male rabbits. Proc Soc Exp Biol Med. 1985:180:144-148.
87. Carlsson M, Svensson K, Erikson E, Carlsson A. Rat brain serotonin: biochemical and functional evidence for a sex differemce. J Neural Transm. 1985;63:297-313.
88. Munaro NI. The effect of ovarian steroids on hypothalamic 5-hydroxytryptamine neuronal activity. Neuroendocrinology. 1978;26:270-276.
89. Kato Y, Matsushita N, Ohta H, Tojo K, Shimatsu A, Imura H. Regulation of prolactin secretion. In: Imura H, ed. The Pituitary Gland. New York, NY: Raven Press; 1985:261-278.
90. Weiner RI, Ganong WF. Monoamines and histamine in regulation of anterior pituitary secretion. Physiol Rev. 1978;58:905-976.
91. Van de Kar LD, Karteszi M, Bethea CL, Ganoong WF. Serotonergic stimulation of prolactin and corticosterone secretion is mediated by different pathways from the mediobasal hypothalamus. Neuroendocrinology. 1985;41:380-384.
92. Montange M, Calas A. Serotonin and endocrinology. In: Osborne NN, Hamon M, eds. Neuronal Serotonin. New York, NY: John Wiley & Sons Inc; 1988:271-303.
93. Gibbs DM, Vale W. Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophyseal portal blood. Brain Res. 1983;280:176-179.
94. Calogero AE, Bernardini R, Margioris AN, Bagdy G, Gallucci WT, Munson PJ, Tamarkin L, Tomai TP, Brady L, Gold PW, Chrousos GP. Effects of serotonergic agonists and antagonists on corticotropin-releasing hormone secretion by explanted rat hypothalami. Peptides. 1989;10:189-200.
95. Fuller RW, Snoddy HD. Effect of serotonin-releasing drugs on serum corticosterone concentration in rats. Neuroendocrinology. 1980;31:96-100.
96. Fuller RW. Serotonergic stimulation of pituitaryadrenocortical function in rats. Neuroendocrinology. 1981;32:118-127.
97. Henn FA. Neuropharmacology of learned helplessness. Presented at the Annual Meeting of the Psychiatric Research Society; March 10, 1990; Park City, Utah.